Mark S Cragg (M Cragg, Mark Cragg)

Loop profile Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 53

Top Venues

Journal of immunology (Baltimore, Md. : 1950)

Nature

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal for immunotherapy of cancer

University of Southampton

University of Southampton (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Southampton Sep 01 2010

United Kingdom

Chair in Experimental Cancer Biology :: Cancer Sciences

Education History

University of Southampton Sep 01 1994 - Mar 01 1998

United Kingdom

PHD :: Cancer Sciences

University of Bath Sep 21 1990 - Jun 01 1994

United Kingdom

BSC :: Biochemistry

Publications

Julie Stockis, Thomas Yip, Julia Moreno-Vicente, Oliver T Burton, Youhani Samarakoon, Martijn J Schuijs, Shwetha Raghunathan, Celine Garcia, Weike Luo, Sarah K Whiteside, Shaun Png, Charlotte Simpson, Stela Monk, Ashley Swale, Kelvin Yin, Johanna Barbieri, Panagiotis Papadopoulos, Ηαnnah E Wong, Hans-Reimer Rodewald, Timothy J Vyse, Andrew N J McKenzie, Mark S Cragg, Matthew Hoare, David R Withers, Hans Joerg Fehling, Rahul Roychoudhuri, Adrian Liston, Timotheus Y F Halim
Cross-talk between ILC2 and Gata3 high T regs locally constrains adaptive type 2 immunity. Science immunology 9 (97) (2024)
Jane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, David Kilian, Laura Bover, Kui S Voo, Kerry L Cox, Tom Murray, Mel John, Hong Shi, Paul Bojczuk, Junping Jing, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Tatyana Inzhelevskaya, Chris A Penfold, C Ian Mockridge, Vikki English, Sara J Brett, Roopa Srinivasan, Christopher Hopson, James Smothers, Axel Hoos, Elaine Paul, Stephen L Martin, Peter J Morley, Niranjan Yanamandra, Mark S Cragg
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations. Journal for immunotherapy of cancer 12 (7) (2024)
Jenna Kelly Dick, Dustin Hicks, Venkatramana D Krishna, Jules A Sangala, Benjamin T Zandstra, Carly A Baehr, J Sjef Verbeek, Mark S Cragg, Maxim C-J Cheeran, Marco Pravetoni, Geoffrey Thomas Hart
ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2. bioRxiv : the preprint server for biology (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Jane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, David Kilian, Laura Bover, Kui S Voo, Kerry L Cox, Tom Murray, Mel John, Hong Shi, Paul Bojczuk, Junping Jing, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Tatyana Inzhelevskaya, Chris A Penfold, C Ian Mockridge, Vikki English, Sara J Brett, Roopa Srinivasan, Christopher Hopson, James Smothers, Axel Hoos, Elaine Paul, Stephen L Martin, Peter J Morley, Niranjan Yanamandra, Mark S Cragg
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations. Journal for immunotherapy of cancer 12 (7) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Julie Stockis, Thomas Yip, Julia Moreno-Vicente, Oliver T Burton, Youhani Samarakoon, Martijn J Schuijs, Shwetha Raghunathan, Celine Garcia, Weike Luo, Sarah K Whiteside, Shaun Png, Charlotte Simpson, Stela Monk, Ashley Swale, Kelvin Yin, Johanna Barbieri, Panagiotis Papadopoulos, Ηαnnah E Wong, Hans-Reimer Rodewald, Timothy J Vyse, Andrew N J McKenzie, Mark S Cragg, Matthew Hoare, David R Withers, Hans Joerg Fehling, Rahul Roychoudhuri, Adrian Liston, Timotheus Y F Halim
Cross-talk between ILC2 and Gata3 high T regs locally constrains adaptive type 2 immunity. Science immunology 9 (97) (2024)
Jane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, David Kilian, Laura Bover, Kui S Voo, Kerry L Cox, Tom Murray, Mel John, Hong Shi, Paul Bojczuk, Junping Jing, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Tatyana Inzhelevskaya, Chris A Penfold, C Ian Mockridge, Vikki English, Sara J Brett, Roopa Srinivasan, Christopher Hopson, James Smothers, Axel Hoos, Elaine Paul, Stephen L Martin, Peter J Morley, Niranjan Yanamandra, Mark S Cragg
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations. Journal for immunotherapy of cancer 12 (7) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Jane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, David Kilian, Laura Bover, Kui S Voo, Kerry L Cox, Tom Murray, Mel John, Hong Shi, Paul Bojczuk, Junping Jing, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Tatyana Inzhelevskaya, Chris A Penfold, C Ian Mockridge, Vikki English, Sara J Brett, Roopa Srinivasan, Christopher Hopson, James Smothers, Axel Hoos, Elaine Paul, Stephen L Martin, Peter J Morley, Niranjan Yanamandra, Mark S Cragg
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations. Journal for immunotherapy of cancer 12 (7) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature (2023)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature 614 (7948) (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature (2023)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Shreyanshi Sonar, Benjamin Sale, Isla Henderson, Luis Del Rio, Peter W M Johnson, Yosef Landesman, Mark S Cragg, Francesco Forconi, Christopher J Walker, Salim I Khakoo, Matthew D Blunt
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia (2023)
Michael J E Marshall, Alexander Knaupp, Christian Spick, Ilker Koese, Maria Maier, Mark S Cragg, Florian Cymer, Tilman Schlothauer
Development of C1q Affinity Chromatography for the Study of C1q-IgG Interactions. Journal of immunology (Baltimore, Md. : 1950) (2023)
Michael J E Marshall, Alexander Knaupp, Christian Spick, Ilker Koese, Maria Maier, Mark S Cragg, Florian Cymer, Tilman Schlothauer
Development of C1q Affinity Chromatography for the Study of C1q-IgG Interactions. Journal of immunology (Baltimore, Md. : 1950) 210 (11) (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature (2023)
Michael J E Marshall, Alexander Knaupp, Christian Spick, Ilker Koese, Maria Maier, Mark S Cragg, Florian Cymer, Tilman Schlothauer
Development of C1q Affinity Chromatography for the Study of C1q-IgG Interactions. Journal of immunology (Baltimore, Md. : 1950) (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature 614 (7948) (2023)
Michael J E Marshall, Alexander Knaupp, Christian Spick, Ilker Koese, Maria Maier, Mark S Cragg, Florian Cymer, Tilman Schlothauer
Development of C1q Affinity Chromatography for the Study of C1q-IgG Interactions. Journal of immunology (Baltimore, Md. : 1950) (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature 614 (7948) (2023)
Xiaojie Yu, Christian M Orr, H T Claude Chan, Sonya James, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Kerry L Cox, Jonathan W Essex, Ivo Tews, Martin J Glennie, Mark S Cragg
Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature (2023)
Franziska Heckel, Anna H Turaj, Hayden Fisher, H T Claude Chan, Michael J E Marshall, Osman Dadas, Christine A Penfold, Tatyana Inzhelevskaya, C Ian Mockridge, Diego Alvarado, Ivo Tews, Tibor Keler, Stephen A Beers, Mark S Cragg, Sean H Lim
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Communications biology 5 (1) (2022)
Christian M Orr, Hayden Fisher, Xiaojie Yu, H T Claude Chan, Yunyun Gao, Patrick J Duriez, Steven G Booth, Isabel Elliott, Tatyana Inzhelevskaya, Ian Mockridge, Christine A Penfold, Armin Wagner, Martin J Glennie, Ann L White, Jonathan W Essex, Arwen R Pearson, Mark S Cragg, Ivo Tews
Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Science immunology 7 (73) (2022)
Khiyam Hussain, Rena Liu, Rosanna C G Smith, Kri T J Müller, Mohammadmersad Ghorbani, Sofia Macari, Kirstie L S Cleary, Robert J Oldham, Russell B Foxall, Sonya James, Steven G Booth, Tom Murray, Lekh N Dahal, Chantal E Hargreaves, Robert S Kemp, Jemma Longley, James Douglas, Hannah Markham, Serena J Chee, Richard J Stopforth, Ali Roghanian, Matthew J Carter, Christian H Ottensmeier, Bjorn Frendéus, Ramsey I Cutress, Ruth R French, Martin J Glennie, Jonathan C Strefford, Stephen M Thirdborough, Stephen A Beers, Mark S Cragg
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. Journal of experimental & clinical cancer research : CR 41 (1) (2022)
Matthew D Blunt, Sócrates Herrera Valencia, Jack G Fisher, Lara V Graham, Amber D P Doyle, Rebecca Fulton, Matthew J Carter, Marta E Polak, Peter W M Johnson, Mark S Cragg, Francesco Forconi, Salim I Khakoo
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. Journal of immunology (Baltimore, Md. : 1950) 209 (2) (2022)
Mark S Cragg
(SUMO)-wrestling with rituximab. Blood 139 (18) (2022)
Xiaojie Yu, Sonya James, James H Felce, Blanka Kellermayer, David A Johnston, H T Claude Chan, Christine A Penfold, Jinny Kim, Tatyana Inzhelevskaya, C Ian Mockridge, Yasunori Watanabe, Max Crispin, Ruth R French, Patrick J Duriez, Leon R Douglas, Martin J Glennie, Mark S Cragg
TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity. Communications biology 4 (1) (2021)
Jonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N Potter, Matthew J J Rose-Zerilli, Laurie H Sehn, Marek Trněný, Umberto Vitolo, Christopher R Bolen, Christian Klein, Andrea Knapp, Mikkel Z Oestergaard, Mark S Cragg
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood advances 5 (15) (2021)
Khiyam Hussain, Mark S Cragg, Stephen A Beers
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies. Cancers 13 (19) (2021)
Joshua M Sopp, Shirley J Peters, Tania F Rowley, Robert J Oldham, Sonya James, Ian Mockridge, Ruth R French, Alison Turner, Stephen A Beers, David P Humphreys, Mark S Cragg
On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation. Communications biology 4 (1) (2021)
Malgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, Chantal E Hargreaves, Chern Lee, Russell Foxall, Matthew J Carter, Stephen A Beers, Kathleen N Potter, Christopher R Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew J J Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W Scott, Laurie H Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trněný, Christopher K Rushton, Graham W Slack, Pedro Farinha, Jonathan C Strefford, Mikkel Z Oestergaard, Ryan D Morin, Mark S Cragg
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood advances 5 (15) (2021)
Jordana Griffiths, Khiyam Hussain, Hannah L Smith, Theodore Sanders, Kerry L Cox, Monika Semmrich, Linda Mårtensson, Jinny Kim, Tatyana Inzhelevskaya, Chris A Penfold, Alison L Tutt, C Ian Mockridge, Ht Claude Chan, Vikki English, Ruth F French, Ingrid Teige, Aymen Al-Shamkhani, Martin J Glennie, Bjorn L Frendeus, Jane E Willoughby, Mark S Cragg
Domain binding and isotype dictate the activity of anti-human OX40 antibodies. Journal for immunotherapy of cancer 8 (2) (2021)
Rena Liu, Robert J Oldham, Emma Teal, Stephen A Beers, Mark S Cragg
Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment. Antibodies (Basel, Switzerland) 9 (4) (2020)
Julie Preillon, Julia Cuende, Virginie Rabolli, Lucile Garnero, Marjorie Mercier, Noémie Wald, Angela Pappalardo, Sofie Denies, Diane Jamart, Anne-Catherine Michaux, Romain Pirson, Vincent Pitard, Martine Bagot, Shruthi Prasad, Erica Houthuys, Margreet Brouwer, Reece Marillier, Florence Lambolez, Joäo R Marchante, Florence Nyawouame, Mathew J Carter, Véronique Baron-Bodo, Anne Marie-Cardine, Mark S Cragg, Julie Déchanet-Merville, Gregory Driessens, Catherine Hoofd
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies. Molecular cancer therapeutics 20 (1) (2020)
Elizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, Johanna Richter, Yohannes Gebreselassie, Matthew J Carter, Jana Karolova, Michael Svaton, Karel Helman, Nicola J Weston-Bell, Laura Karydis, Chris T Williamson, Georg Lenz, Jeremy Pettigrew, Curtis Harwig, Freda K Stevenson, Mark S Cragg, Francesco Forconi, Andrew J Steele, Jennifer Cross, Lloyd Mackenzie, Pavel Klener, Graham Packham
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (7) (2019)
Alex Bersellini Farinotti, Gustaf Wigerblad, Diana Sofia Marques Nascimento, Duygu B Bas, Carlos Morado Urbina, Kutty Selva Nandakumar, Katalin Sandor, Bingze Xu, Sally Abdelmoaty, Matthew A Hunt, Kristina Ängeby Möller, Azar Baharpoor, Jon Sinclair, Kent Jardemark, Johanna T Lanner, Ia Khmaladze, Lars E Borm, Lu Zhang, Fredrik Wermeling, Mark S Cragg, Johan Lengqvist, Anne-Julie Chabot-Doré, Luda Diatchenko, Inna Belfer, Mattias Collin, Kim Kultima, Birgitta Heyman, Juan Miguel Jimenez-Andrade, Simone Codeluppi, Rickard Holmdahl, Camilla I Svensson
Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons. The Journal of experimental medicine 216 (8) (2019)
Ali Roghanian, Guangan Hu, Christopher Fraser, Maneesh Singh, Russell B Foxall, Matthew J Meyer, Emma Lees, Heather Huet, Martin J Glennie, Stephen A Beers, Sean H Lim, Margaret Ashton-Key, Stephen M Thirdborough, Mark S Cragg, Jianzhu Chen
Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression. Cancer immunology research 7 (11) (2019)
Lindsay D Smith, Annabel R Minton, Matthew D Blunt, Laura I Karydis, David A Dutton, Karly-Rai Rogers-Broadway, Rachel Dobson, Rena Liu, Faith Norster, Elizabeth K J Hogg, Margaret Ashton-Key, Jonathan C Strefford, Li Jia, Dimitar G Efremov, G Vignir Helgason, Peter W M Johnson, Freda K Stevenson, Francesco Forconi, Mark S Cragg, David A Tumbarello, Graham Packham, Andrew J Steele
BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia 34 (2) (2019)
Richard J Stopforth, Robert J Oldham, Alison L Tutt, Patrick J Duriez, H T Claude Chan, Brock F Binkowski, Chad Zimprich, Dun Li, Philip G Hargreaves, Mei Cong, Venkat Reddy, Maria J Leandro, Geraldine Cambridge, Anja Lux, Falk Nimmerjahn, Mark S Cragg
Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB. Journal of immunology (Baltimore, Md. : 1950) 200 (5) (2018)
Adam Palazzo, Sylvia Herter, Laura Grosmaire, Randy Jones, Christian R Frey, Florian Limani, Marina Bacac, Pablo Umana, Robert J Oldham, Michael J E Marshall, Kerry L Cox, Anna H Turaj, Mark S Cragg, Christiane Neumann, Matthew J Carter, Stacey Tannheimer
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. Journal of immunology (Baltimore, Md. : 1950) 200 (7) (2018)
Anna H Turaj, Kerry L Cox, Christine A Penfold, Ruth R French, C Ian Mockridge, Jane E Willoughby, Alison L Tutt, Jordana Griffiths, Peter W M Johnson, Martin J Glennie, Ronald Levy, Mark S Cragg, Sean H Lim
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Scientific reports 8 (1) (2018)
Harvey E Johnston, Matthew J Carter, Kerry L Cox, Melanie Dunscombe, Antigoni Manousopoulou, Paul A Townsend, Spiros D D Garbis, Mark S Cragg
Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures. Molecular & cellular proteomics : MCP 16 (3) (2017)
T Klymenko, J Bloehdorn, J Bahlo, S Robrecht, G Akylzhanova, K Cox, S Estenfelder, J Wang, J Edelmann, J C Strefford, T K Wojdacz, K Fischer, M Hallek, S Stilgenbauer, Mark S Cragg, J Gribben, Andrejs Braun
Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia 32 (2) (2017)
Kirstie L S Cleary, H T Claude Chan, Sonja James, Martin J Glennie, Mark S Cragg
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. Journal of immunology (Baltimore, Md. : 1950) 198 (10) (2017)
Chantal E Hargreaves, Matthew J J Rose-Zerilli, Lee R Machado, Chisako Iriyama, Edward J Hollox, Mark S Cragg, Jonathan C Strefford
Fcγ receptors: genetic variation, function, and disease. Immunological reviews 268 (1) (2016)
Samantha D Pauls, Arnab Ray, Sen Hou, Andrew T Vaughan, Mark S Cragg, Aaron J Marshall
FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells. Journal of immunology (Baltimore, Md. : 1950) 197 (5) (2016)
Thomas R W Tipton, C Ian Mockridge, Ruth R French, Alison L Tutt, Mark S Cragg, Stephen A Beers
Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo. Blood 126 (24) (2015)
Alison L Tutt, Sonya James, Stéphanie A Laversin, Thomas R W Tipton, Margaret Ashton-Key, Ruth R French, Khiyam Hussain, Andrew T Vaughan, Lang Dou, Alexander Earley, Lekh N Dahal, Chen Lu, Melanie Dunscombe, H T Claude Chan, Christine A Penfold, Jinny H Kim, Elizabeth A Potter, C Ian Mockridge, Ali Roghanian, Robert J Oldham, Kerry L Cox, Sean H Lim, Ingrid Teige, Bjorn Frendéus, Martin J Glennie, Stephen A Beers, Mark S Cragg
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors. Journal of immunology (Baltimore, Md. : 1950) 195 (11) (2015)

Mark S Cragg.css-eqlu8i{font-size:small;padding-left:4px;} (M Cragg, Mark Cragg)

Publication Activity (10 Years)

Top Topics

Top Venues

Mark S Cragg (M Cragg, Mark Cragg)